Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?

Merck (MRK) reported mixed Q2 results, beating earnings while meeting sales, and subsequently narrowed its 2025 revenue guidance to $64.3B-$65.3B, though it slightly raised the lower end of its EPS range, benefiting from a reduced currency headwind. This revised outlook, which notably excludes the pending $10 billion Verona Pharma acquisition, signals cautious expectations for the second half of 2025 amidst competitive and economic pressures. Despite this, Keytruda sales grew 9% to $7.96 billion, comprising half of pharma revenues, and new products like Winrevair and Capvaxive demonstrated strong initial uptake, positioning them as crucial future growth drivers as the company prepares for Keytruda's 2028 exclusivity loss.

Analysis

Merck presented a mixed financial picture following its second-quarter results, meeting sales estimates but delivering an earnings beat. The company subsequently narrowed its full-year 2025 revenue guidance to a range of $64.3-$65.3 billion, tightening the band despite a reduced negative currency impact of 0.5%. Simultaneously, the lower end of the adjusted EPS forecast was raised to $8.87. This revised outlook, which excludes the impact of the pending $10 billion acquisition of Verona Pharma, signals a cautious operational stance for the second half of the year. Growth continues to be anchored by the flagship oncology drug Keytruda, which saw sales rise 9% year-over-year to $7.96 billion, now constituting approximately 50% of the company's pharmaceutical revenues. Critically, new products are demonstrating strong early traction, with pulmonary arterial hypertension (PAH) drug Winrevair and vaccine Capvaxive posting sequential sales growth of 20% and 20.1% respectively. These products are positioned as vital long-term growth drivers to offset Keytruda's patent expiration in 2028, though Winrevair faces a highly competitive PAH market dominated by Johnson & Johnson and United Therapeutics. Despite the cautious guidance, the stock's valuation appears attractive, trading at a forward P/E of 8.64, significantly below its 5-year average of 12.79 and the industry's 13.71, even as its shares have underperformed the industry year-to-date with an 18.8% loss.

Key Decisions for Investors

• Given the stock's 18.8% YTD underperformance and a forward P/E of 8.64, well below historical and industry averages, value-focused investors may see an attractive entry point despite the cautious outlook.
• Investors should closely monitor the quarterly sales performance of new products Winrevair and Capvaxive, as their growth trajectory is the primary catalyst to de-risk the company's dependency on Keytruda ahead of its 2028 patent cliff.
• Monitor competitive dynamics in the PAH market, particularly sales figures from Johnson & Johnson and United Therapeutics, as this will determine Winrevair's market share capture and long-term revenue potential.
• Factor in that current guidance excludes the $10 billion Verona Pharma acquisition, and look for its successful closure in Q4 2025 to serve as a potential positive catalyst for future growth.